Because of the large and still increasing number of secretagogues acting by MRGPRX2 activation, the receptor has become the spotlight of MC research and is linked to a number of diseases triggered by non-immunological MC activation, including injection-site hypersensitivity reactions, chronic urticaria, atopic dermatitis, red man syndrome, periodontitis, and drug anaphylaxis [1,3,5,12,15,53]. This evidence concerns the gene MRGPRX2 and atopic eczema.